KPIs & Operating Metrics(New)
Growth Metrics

Charles River Laboratories International (CRL) EPS (Weighted Average and Diluted) (2016 - 2025)

Charles River Laboratories International has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at -$5.56 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$5.56 for Q4 2025, down 33.33% from a year ago — trailing twelve months through Dec 2025 was -$2.9 (down 1550.0% YoY), and the annual figure for FY2025 was -$2.91, down 1555.0%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$5.56 at Charles River Laboratories International, down from $1.1 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CRL hit a ceiling of $3.65 in Q4 2022 and a floor of -$5.56 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $1.73 (2021), compared with a mean of $1.18.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 50.83% in 2022 and later plummeted 214.56% in 2024.
  • Charles River Laboratories International's EPS (Weighted Average and Diluted) stood at $2.67 in 2021, then skyrocketed by 36.7% to $3.65 in 2022, then dropped by 0.27% to $3.64 in 2023, then plummeted by 214.56% to -$4.17 in 2024, then crashed by 33.33% to -$5.56 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$5.56 (Q4 2025), $1.1 (Q3 2025), and $1.06 (Q2 2025) per Business Quant data.